The impact of CYP2D6 and CYP2C19 Polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: A retrospective study

Therapeutic Drug Monitoring

Volumn 30, Issue 3, 2008, Pages 265-270

  Kobylecki, Camilla J ^a   Hansen, Thomas ^a,b   Timm, Sally ^a   Wang, August ^a   Jakobsen, Klaus D ^a   Sørensen, Holger J ^a   Rasmussen, Henrik B ^a   Werge, Thomas ^a  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Compliance; CYP2C19; CYP2D6; Poor metabolizers; Side effects; Treatment failure

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; PSYCHOTROPIC AGENT; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; NEUROLEPTIC AGENT; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CLINICAL EVALUATION; DRUG DEPENDENCE; DRUG METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; TREATMENT FAILURE; ADDICTION; ANALYSIS OF VARIANCE; GENETICS; MIDDLE AGED; PATIENT COMPLIANCE; PHENOTYPE; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; RISK; STATISTICAL MODEL; STATISTICS; SUICIDE; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; ODDS RATIO; PATIENT COMPLIANCE; PHENOTYPE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; SUICIDE; TREATMENT OUTCOME;

EID: 47249097440     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31817721d6     Document Type: Article

References (32)

1. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-73.
2. Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007;120:S26-S31.
3. Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics. 2001;1:3-10.
4. Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest. 2003;33:17-22.
5. de LJ, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47:75-85.
6. Scordo MG,Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics. 2002;3:201-218.
7. Goswami S, Mattoo SK, Basu D, et al. Substance-abusing schizophrenics: do they self-medicate? Am J Addict. 2004;13:139-150.
8. Heila H, Isometsa ET, Henriksson MM, et al. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry. 1999;60:200-208.
9. Taiminen TJ, Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. Acta Psychiatr Scand. 1994;90:247-251.
10. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict. 2006;15:345-355.
11. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998;23:717-734.
12. Bartels SJ, Drake RE. Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry. 1988;29:467-483.
13. Pompili M, Mancinelli I, Girardi P, et al. Preventing suicide in young schizophrenics who are substance "abusers." Subst Use Misuse. 2004;39: 1435-1439.
14. Harkavy-Friedman JM, Restifo K, Malaspina D, et al. Suicidal behavior in schizophrenia: characteristics of individuals who had and had not attempted suicide. Am J Psychiatry. 1999;156:1276-1278.
15. Hunt IM, Kapur N, Windfuhr K, et al. Suicide in schizophrenia: findings from a national clinical survey. J Psychiatr Pract. 2006;12:139-147.
16. Munk-Jorgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44:82-84.
17. Hansen T, Hemmingsen RP, Wang AG, et al. Apolipoprotein D is associated with long-term outcome in patients with schizophrenia. Pharmacogenomics J. 2006;6:120-125.
18. Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998;8:15-26.
19. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
20. De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
21. Ferguson RJ, De Morais SM, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 1998;284: 356-361.
22. Ibeanu GC, Blaisdell J, Ferguson RJ, et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999;290: 635-640.
23. Douglas AM, Atchison BA, Somogyi AA, et al. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics. 1994;4:154-158.
24. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 1996;272:210-218.
25. Hersberger M, Marti-Jaun J, Rentsch K, et al. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem. 2000;46: 1072-1077.
26. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-34.
27. Jakobsen KD, Frederiksen JN, Hansen T, et al. Reliability of clinical ICD-10 schizophrenia diagnoses. Nord J Psychiatry. 2005;59:209-212.
28. Acosta FJ, Aguilar EJ, Cejas MR, et al. Are there subtypes of suicidal schizophrenia? A prospective study. Schizophr Res. 2006;86: 215-220.
29. Rasmussen JO, Christensen M, Svendsen JM, et al. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest. 2006; 66:129-136.
30. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187:9-20.
31. Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15: 127-135.
32. Lester D. Sex differences in completed suicide by schizophrenic patients: a meta-analysis. Suicide Life Threat Behav. 2006;36:50-56.